FDA approves lusutrombopag for thrombocytopenia

1 August 2018
shionogi-big

The US Food and Drug Administration approved Mulpleta (lusutrombopag) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

The New Drug Application (NDA) for lusutrombopag (S-888711) was accepted for filing in February this year, as was the marketing application to the European Medicines Agency. Lusutrombopag was approved by the Ministry of Health, Labor and Welfare in Japan in September 2015.

The approval, granted to Japan’s Shionogi (TYO: 4507), was based on two randomized, double-blind, placebo-controlled trials (L-PLUS 1 and L-PLUS 2, NCT02389621) involving 312 patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure and had a platelet count less than 50 x 109/L. Patients were randomized 1:1 to receive 3mg of lusutrombopag or placebo once daily for up to 7 days.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical